What is Tempest Therapeutics Inc?
, a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 7.64M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.